At the news
? NEUTRALIMPACT 3/10 144 filed Apr 1, 2026 at 16:42 ET
Elena Ridloff, a director at Kymera Therapeutics, filed a Form 144 to sell up to 4,600 shares, following the exercise of stock options. This sale is part of a pre-arranged 10b5-1 trading plan and follows recent insider selling activity totaling $3.8M in the past 30 days.
- Elena Ridloff, director of Kymera Therapeutics, filed Form 144 to sell up to 4,600 shares.
- The shares were acquired through the exercise of stock options on March 31, 2026, and the sale is planned for April 1, 2026.
- This is part of a pre-arranged 10b5-1 plan, indicating non-discretionary timing.
- Ridloff has already sold 7,400 shares on March 31, 2026, for approximately $631,739.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access